AIP
ABBV icon

Almanack Investment Partners’s AbbVie ABBV Stock Holding History

Almanack Investment Partners’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.34M Buy
5,322
+4,257
+400% +$916K 0.17% 83
2026
Q1 		$232K Sell
1,065
-145
-12% -$32.2K 0.04% 154
2025
Q4 		$276K Buy
+1,210
New +$276K 0.05% 141
2025
Q3 		– Sell
-10,554
Closed -$1.96M – 198
2025
Q2 		$1.96M Buy
10,554
+9,128
+640% +$1.7M 0.31% 45
2025
Q1 		$299K Buy
1,426
+7
+0.5% +$1.36K 0.06% 115
2024
Q4 		$252K Hold
1,419
– – 0.04% 155
2024
Q3 		$280K Buy
+1,419
New +$265K 0.04% 149
2022
Q4 		– Sell
-1,770
Closed -$238K – 173
2022
Q3 		$238K Sell
1,770
-4,887
-73% -$701K 0.05% 125
2022
Q2 		$1.02M Buy
6,657
+3,328
+100% +$509K 0.1% 136
2022
Q1 		$540K Buy
3,329
+143
+4% +$20.8K 0.05% 246
2021
Q4 		$431K Sell
3,186
-179
-5% -$21.1K 0.03% 286
2021
Q3 		$363K Buy
3,365
+315
+10% +$36K 0.03% 329
2021
Q2 		$344K Sell
3,050
-486
-14% -$54.7K 0.03% 292
2021
Q1 		$383K Buy
3,536
+825
+30% +$88.2K 0.04% 279
2020
Q4 		$291K Sell
2,711
-7,494
-73% -$720K 0.03% 290
2020
Q3 		$1.02M Buy
10,205
+811
+9% +$76.4K 0.13% 105
2020
Q2 		$922K Buy
+9,394
New +$827K 0.16% 70
2019
Q3 		– Sell
-1,945
Closed -$141K – 231
2019
Q2 		$141K Buy
+1,945
New +$153K 0.03% 224
2019
Q1 		– Sell
-1,156
Closed -$107K – 144
2018
Q4 		$107K Sell
1,156
-72
-6% -$6.33K 0.03% 228
2018
Q3 		$108K Sell
1,228
-1,442
-54% -$137K 0.03% 254
2018
Q2 		$247K Sell
2,670
-112
-4% -$10.9K 0.11% 83
2018
Q1 		$263K Buy
2,782
+1
+0% +$110 0.1% 85
2017
Q4 		$269K Buy
2,781
+322
+13% +$30.3K 0.11% 92
2017
Q3 		$219K Sell
2,459
-638
-21% -$48.6K 0.11% 86
2017
Q2 		$225K Buy
+3,097
New +$208K 0.13% 106

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Almanack Investment Partners's ABBV Position: Q2 2026 in Review

Almanack Investment Partners increased its AbbVie (ABBV) stake by 400% in Q2 2026, buying an estimated $916K and bringing the position to 5,322 shares worth $1.34M. The position accounts for 0.17% of the portfolio, ranked #83.

Almanack Investment Partners first reported a position in ABBV in Q2 2017 and has held it in 25 quarters since. The position peaked at $1.96M in Q2 2025. 4,189 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Almanack Investment Partners held 5,322 shares of AbbVie worth $1.34M as of Q2 2026.
  • Almanack Investment Partners bought 4,257 AbbVie shares in Q2 2026, an estimated $916K.
  • AbbVie made up 0.17% of Almanack Investment Partners's portfolio in Q2 2026, its #83 holding.
  • Almanack Investment Partners first reported a position in AbbVie in Q2 2017 and has held it in 25 quarters since.
  • Almanack Investment Partners's AbbVie position peaked at $1.96M in Q2 2025.
  • 4,189 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Almanack Investment Partners's 13F filing for Q2 2026, filed 30 Jul 2026.